FDA appears willing to allow some flexibility for compounders who must adhere to Good Manufacturing Practices, allowing for potential alternatives to minimize the burden of some testing requirements.
GMP Flexibility For Compounders Signaled In FDA Draft Guidance
Agency seeks comments on how to minimize burden of some testing requirements for registered outsourcing facilities.
More from United States
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
• By
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
• By
Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
FDA Commissioner Martin Makary was sworn in Friday and knew of the plan that ultimately lead to CBER director Peter Marks' resignation on 28 March.